Psychopharmacology

Jelena Kunovac, MD, MS, discusses last week's approval of Cobenfy, an agent with a novel mechanism of action that could revolutionize schizophrenia treatment.

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

Although the Model Curriculum for Teachers of Psychopharmacology has evolved over 2 decades, it continues to provide practical and easy to use resources for psychiatric educators from leading experts.

A review and meta-analysis of antipsychotic dose-response literature prompts a proposal for lower maximum target doses.

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

Psychiatry is such a young field attempting to improve functioning and quality of life for so many diverse and complex brain disorders that it should be no surprise that our treatment outcomes spread across the spectrum from much improved to progressive decline.

Write to us now to be part of our series on treatment updates this month.

In this CME article, review management of several clozapine-related adverse effects and outline considerations when addressing inadequate positive symptom response to clozapine.

The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.

To expertly utilize polypharmacy, it is imperative that clinicians stay abreast of new literature, check for drug-drug interactions, and be aware of emerging trends in drug use.

The 2024 American Society of Clinical Psychopharmacology Annual Meeting brought together researchers and clinicians to engage in discussion, education, and dissemination of research findings and new methodologies.

While ketamine is a not approved for the treatment of depression or chronic pain, clinicians have shown increased interest in using it for these conditions. An FDA workshop is exploring its potential.

Here are highlights from the week in Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

What is their comparative safety?

The CDC suggests that disrupted access to ADHD medications may increase risk of overdose and injury.

Recent research sheds light on which antidepressants should be preferred as a first option for long-term use.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.